Swiss pharma major Novartis has reported that its oral candidate remibrutinib significantly cut relapse rates against French ...

Medicines regulators in major international markets have issued a run of first-in-class approvals, safety communications, ...

French biotech firm Inventiva (Euronext: IVA) has appointed Chris Benecchi as chief operating officer, completing its ...

A clinical-stage cell therapy company developing autologous and allogeneic switchable CAR-T cell therapies. In October 2024, AvanCell announced that it raised $112 million in Series B financing, which ...

The 2026 theme is "Data to Dialogue: Communicating Radiotherapy's Value to Advance Care". The 68th annual meeting runs from ...

Waltham, Massachusetts-based advanced therapy contract development and manufacturing organization (CDMO) and gene editing ...

The World Conference on Lung Cancer is the annual meeting of the International Association for the Study of Lung Cancer, covering the full span of thoracic oncology from screening through to treatment ...

Beam Therapeutics, a Cambridge, Massachusetts-based biotech developing precision genetic medicines through base editing, announced Tuesday the appointment of Eric Foster as chief commercial officer ...

The US Food and Drug Administration has approved Besremi (ropeginterferon alfa-2b-njft) injection for the treatment of adults with essential thrombocythemia, from Taiwan-based PharmaEssentia.

Immunic, a late-stage biotech developing oral therapies for neurological diseases, has appointed Chitrang Davé as chief data ...

Sino-American oncology-focused biotech BeOne Medicines has announced positive top-line results from the second interim ...

Swiss pharma giant Novartis said its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib met their primary endpoint, ...